Successful Hemostasis with Extended Half-life Recombinant Factor VIII in Circumcision

Intensified coagulation factor replacement is essential for surgical procedures in people with hemophilia A (HA). It is indicated during surgery and in the postoperative period [1,2]. The efficacy and the safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in prophylaxis and treatment of bleeding episodes have already been reported and its half-life in the circulation was proven to be 1.5 times longer compared to standard half-life FVIII (SHL-FVIII) [3]. Circumcision is a common surgical intervention in approximately half of the world [4,5]. In this report, we aimed to present our experience with extended half-life recombinant FVIII (EHL-rFVIII)-BAX 855 treatment for circumcision in two severe cases of HA.


To the Editor,
Intensified coagulation factor replacement is essential for surgical procedures in people with hemophilia A (HA). It is indicated during surgery and in the postoperative period [1,2]. The efficacy and the safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in prophylaxis and treatment of bleeding episodes have already been reported and its half-life in the circulation was proven to be 1.5 times longer compared to standard half-life FVIII (SHL-FVIII) [3]. Circumcision is a common surgical intervention in approximately half of the world [4,5]. In this report, we aimed to present our experience with extended half-life recombinant FVIII (EHL-rFVIII)-BAX 855 treatment for circumcision in two severe cases of HA.
The first patient was diagnosed at the age of 3 months with severe HA (factor VIII = 0.001 IU/mL=0.1%) with no family history.
He started primary prophylaxis twice a week at the age of 17 months; however, his prophylaxis regimen had to be changed to 3 times a week at the age of 5 years old due to frequent bleeding of the elbows. He was enrolled in an EHL-rFVIII clinical trial at 5.5 years old, and the prophylaxis was continued twice a week for 3 years with no bleeding. The second patient was diagnosed at the age of 8 months with severe HA (factor VIII=0.003 IU/mL=0.3%); he had a family history. He began primary prophylaxis twice a week at the age of 15 months. He was enrolled in an EHL-rFVIII clinical trial at 5.5 years old, and prophylaxis was continued twice a week for 3 years with no bleeding. Both patients had no adverse events and no inhibitors during this period. The two patients were circumcised at 8 years old in a pediatric urology clinic. Both patients were hospitalized on the day of circumcision. One patient had phimosis and was hospitalized for 3 days; the other patient was hospitalized for 1 day. Both patients were circumcised under  Circumcision is a cultural and traditional surgical intervention, and many patients want to be circumcised around the world. In previously published series, it was reported that circumcision could be performed with minimal complication rates by using a diathermic knife. In this routine clinical practice, tranexamic acid and SHL-FVIII products have been used for hemostasis with decreasing doses between 4 and 14 days until wound healing occurs, depending on the severity of hemophilia [6,7]. In another protocol in which circumcision was performed under general anesthesia, fibrin glue application with 2-3 days of factor supplementation was found to be sufficient [8]. As we report here, just two extra doses of EHL-rFVIII were needed on postoperative days 1 and 2 for our patients who underwent circumcision. Our experiences with these two patients demonstrate that PEGylated rFVIII is well tolerated and efficacious for bleeding prophylaxis before circumcision.
There are limited data on EHL-rFVIII products in surgical interventions in the literature [9,10,11]. The first such prospective study reported 15 surgical interventions with PEGylated EHL-rFVIII and hemostatic efficacy was excellent for all subjects in both the intraoperative and perioperative period. Additionally, all interventions were scored as excellent postoperatively, except for one dental procedure that was graded as good. In addition, no related adverse events, including thrombosis and inhibitors, were recorded [9]. To the best of our knowledge, this is the first report to indicate two successful circumcision procedures performed under perioperative and postoperative EHL-rFVIII prophylaxis. Additionally, successful prophylaxis was achieved with lower frequency of factor supplementation compared to other series. As we mentioned above, no adverse events, no thrombotic events, and no inhibitor development were observed following prophylaxis.
In conclusion, EHL-rFVIII was safe and effective for circumcision management in cases of severe HA. Decreasing the amount and frequency of factor support seems to be possible according to this report.

Authorship Contributions
Surgical